SAMANSIC SUMO Cellular Beauty & Vitality Assessment System

Business Plan Pitch Deck

​

SLIDE 1: TITLE AND MISSION

SAMANSIC SUMO™
Cellular Beauty & Vitality Assessment System

• Mission: To transform beauty from guesswork into data-driven science by measuring and optimizing cellular health through the emerging science of SUMOylation.

• The SAMANSIC SUMO system represents the world's first comprehensive platform that measures beauty at the cellular level. By combining a professional-grade fingertip pulse oximeter with advanced cellular analysis capabilities, the EGB-AI Omega remote diagnostic platform, and the SAMANSIC SUMO-Generating supplement protocol, this ecosystem provides women with unprecedented insight into the biological processes that determine their appearance, health, and vitality.

​

SLIDE 2: THE PROBLEM

• Beauty is invisible until it is lost. Women invest billions annually in skincare, cosmetics, and beauty treatments, yet they have no objective way to measure whether these investments are actually working at the cellular level. The fundamental problem is that current beauty assessment relies entirely on subjective observation—what we can see in the mirror—rather than objective data about what is happening beneath the surface.

• At the cellular level, a critical process called SUMOylation regulates inflammation, skin health, tissue adaptation to metabolic stress, and hormonal balance. Dysregulated SUMOylation has been implicated in skin conditions including psoriasis, atopic dermatitis, and vitiligo, where alterations in SUMO1-conjugated proteins and SUMOylation-associated enzymes affect keratinocyte proliferation and immune balance. Despite this established scientific connection, no consumer device exists to measure SUMOylation status or provide actionable beauty optimization recommendations based on cellular data.

• The result is a beauty industry built on hope rather than evidence. Women waste money on ineffective products, miss opportunities for true beauty optimization, and remain disconnected from the cellular processes that determine their appearance. This is not just a consumer problem—it is a fundamental gap in how we approach beauty and wellness that demands an innovative solution.

​

SLIDE 3: THE SOLUTION

• The SAMANSIC SUMO Cellular Beauty & Vitality Assessment System provides a comprehensive, integrated solution to the problem of invisible beauty. The system consists of three interconnected components that work together to measure, analyze, and optimize cellular beauty.

• The SCB-VAD device is a professional-grade fingertip pulse oximeter that extends far beyond conventional pulse oximetry. While standard devices measure only blood oxygen saturation and pulse rate, the SCB-VAD employs a multi-wavelength optical sensor array that captures both the standard pulsatile signals and the non-pulsatile components that contain vital information about cellular energy status and tissue adaptation. The device measures Cellular Energy Index (CEi), a proprietary metric indicating cellular vitality and SUMOylation status, along with tissue adaptation scores that reflect SUMOylation-mediated stress adaptation and microcirculation health.

• The EGB-AI Omega platform provides remote AI-powered analysis of the cellular data transmitted from the SCB-VAD. Operating through three integrated layers of consciousness—Unspoofable Awareness, Adaptive Understanding, and Emergent Consciousness—the EGB-AI Omega generates comprehensive beauty assessments by correlating the device's cellular metrics with established beauty biomarkers. The platform analyzes SUMOylation-related parameters, inflammatory status indicators, tissue adaptation scores, and microcirculation health to produce personalized beauty optimization recommendations.

• The SAMANSIC SUMO-Generating supplement protocol provides the intervention component of the ecosystem. Based on the EGB-AI Omega analysis, users receive personalized recommendations for the SAMANSIC SUMO formula, which integrates synbiotic gut-immune-SUMO axis modulation, adaptogenic stress-immune-SUMO modulation through Ashwagandha, Ginseng, Holy Basil, and Suma, foundational nutrient support through vitamins and trace elements essential for SUMO enzymatic function, and targeted SUMO-mediated immune modulation through Anacardic Acid, NMN, Astragalus, Shiitake, and NAC.

​

SLIDE 4: THE TECHNOLOGY

• The SCB-VAD device employs advanced photoplethysmography technology that extends beyond conventional pulse oximetry. The multi-wavelength optical sensor captures both the pulsatile AC components traditionally used for SpO2 calculation and the non-pulsatile DC components that contain vital information about cellular oxygen status and tissue adaptation. The signal processing unit features 24-bit analog-to-digital converters with 16kHz sampling rate, adaptive filtering algorithms for motion artifact reduction, and perfusion index measurement for signal quality assessment. The device calculates the Cellular Energy Index by subtracting the detected infrared value from the detected red value, a proprietary metric that correlates with SUMOylation activity.

• The SCB-VAD provides immediate display of blood oxygen saturation (SpO2) with ±2% accuracy, pulse rate with ±2 bpm accuracy, perfusion index indicating signal quality, Cellular Energy Index, plethysmogram waveform for signal quality verification, and Bluetooth connection status and data transmission confirmation. The OLED display features multi-angle readability and configurable color-coded indicators that provide intuitive understanding of cellular health status.

• Data transmission follows a secure, multi-stage architecture. Raw optical signals are processed by the ARM Cortex-M7 microprocessor, with advanced cellular metrics computed and data packets encrypted using AES-256 prior to transmission. Bluetooth 5.0 LE transmits encrypted data packets to the Tenovi cellular gateway or equivalent hub device, which provides cellular connectivity via 4G/LTE networks. The entire process from measurement to cloud upload takes less than one minute and requires no user intervention beyond placing the finger in the device.

• The EGB-AI Omega platform employs a sophisticated multi-factor algorithm to assess SUMOylation status and its implications for beauty and vitality. The algorithm analyzes the Cellular Oxygen Metabolism Index to determine cellular oxygen utilization efficiency, which correlates with SUMOylation activity as SUMOylation requires proper redox balance for optimal enzymatic function. It detects inflammatory status indicators through patterns in cellular oxygenation that suggest systemic inflammation, and since SUMOylation regulates NF-κB pathway activation and pro-inflammatory cytokine production, the device can infer SUMOylation status from inflammatory markers. The Tissue Adaptation Score measures the cellular response to metabolic stress and adaptation capability, while microcirculation health assessment evaluates perfusion index and capillary function. The algorithm also analyzes sleep and restorative patterns through heart rate variability and cellular oxygenation during monitoring sessions.

​

SLIDE 5: BUSINESS MODEL

• The SAMANSIC SUMO system generates revenue through three complementary streams that create a sustainable, recurring revenue ecosystem.

• The primary revenue stream comes from device sales. The SCB-VAD device is priced as a premium professional-grade beauty assessment tool at $349 to $499, positioning it as an investment in beauty optimization rather than a commodity consumer device. The device provides the gateway to the entire ecosystem, creating a lock-in effect that drives recurring revenue from the other streams.

• The second revenue stream is the SAMANSIC SUMO supplement protocol, delivered as a monthly subscription. Priced at $69.99 to $99.99 per month, the subscription provides personalized formulation based on the EGB-AI Omega analysis. The supplement protocol is a high-margin consumable that creates ongoing customer relationships and predictable recurring revenue. The lock-in effect is strong because the supplements are specifically formulated based on the individual's cellular assessment, making it difficult for competitors to replace the product without the supporting assessment ecosystem.

• The third revenue stream comes from premium analysis reports and professional dashboards. Basic reports are included with the supplement subscription, but premium reports at $29.99 to $49.99 per analysis provide deeper insights and more detailed recommendations. Enterprise and professional dashboards for dermatology practices, aesthetic medicine clinics, and wellness centers are priced at $199 per month, providing comprehensive patient assessment and management capabilities.

• This revenue model is inspired by the success of companies like Oura, which achieved an $11 billion valuation with 5.5 million units sold and recurring subscription revenue. The combination of hardware, subscription, and premium services creates a resilient business model with multiple growth vectors and high customer lifetime value.

​

SLIDE 6: MARKET OPPORTUNITY

• The market opportunity for the SAMANSIC SUMO system is substantial and rapidly growing. The at-home beauty device subscriptions market reached $2.68 billion in 2026 and is projected to reach $16.54 billion by 2036, representing a compound annual growth rate of 19.9 percent. This explosive growth is driven by several key trends that create a favorable environment for the SAMANSIC SUMO system.

• IoT-enabled skin diagnostics are transforming the beauty device market, with consumers increasingly demanding measurable outcomes rather than vague promises. Data personalization is driving retention and recurring revenue, with 51.2 percent of subscription beauty device spending targeting anti-aging applications. Consumers are moving away from one-size-fits-all beauty approaches and seeking personalized solutions based on their individual biology.

• The target market encompasses multiple segments. Premium beauty consumers represent the largest initial opportunity, with women who are already investing heavily in beauty and wellness products but lack objective measurement of their effectiveness. Dermatology and aesthetic medicine practices need objective cellular assessment tools to optimize treatments and demonstrate outcomes. Wellness and spa centers are seeking differentiated offerings that provide measurable value to their clients. Health-conscious professionals in high-stress environments need to monitor and optimize their cellular health proactively.

• The total addressable market includes all women who invest in beauty and wellness products, representing hundreds of billions in annual spending. The serviceable available market consists of premium beauty consumers who are already using technology-enabled beauty solutions and are willing to invest in data-driven optimization. The serviceable obtainable market in the first three to five years includes early adopters who are receptive to cellular-level beauty assessment and optimization.

​

SLIDE 7: COMPETITIVE ADVANTAGE

• The SAMANSIC SUMO system has no direct competitors, creating a first-mover advantage in the emerging category of cellular beauty measurement. No existing device combines cellular beauty assessment, SUMOylation analysis, remote AI diagnostics, supplement integration, and beauty-optimized reports in a single integrated ecosystem.

• Oura Ring provides wellness monitoring but does not offer beauty-specific cellular assessment or SUMOylation analysis. Swan Beauty Mirror offers AI-powered skin analysis but lacks cellular-level measurement and supplement integration. Traditional pulse oximeters measure only blood oxygen saturation and pulse rate, providing no beauty-specific insights. The SAMANSIC SUMO system is the only platform that measures beauty at the cellular level and provides evidence-based intervention guidance.

• The unique value proposition is supported by substantial scientific evidence. Research demonstrates that SUMOylation plays an established regulatory role in both innate and adaptive immunity, influencing the development of pro-inflammatory cytokines and the activation of key inflammatory pathways. Short-chain fatty acids and branched-chain fatty acids produced by gut commensal bacteria increase protein SUMOylation in intestinal cells, inactivating intestinal deSUMOylases and inhibiting the NF-κB pathway. SUMOylation plays a crucial role in tissue adaptation to metabolic stress, enabling cells to survive in stressful situations.

• The proprietary technology creates significant barriers to entry. The multi-wavelength optical sensor design, Cellular Energy Index calculation algorithm, SUMOylation assessment algorithm, and EGB-AI Omega platform are all proprietary intellectual property. The clinical validation data establishing correlation between SCB-VAD metrics and SUMOylation biomarkers provides a data advantage that would be difficult for competitors to replicate.

​

SLIDE 8: GO-TO-MARKET STRATEGY

• The go-to-market strategy follows a phased approach designed to build credibility, demonstrate value, and scale to mass market adoption.

• Phase one is the premium launch, targeting months one through six. This phase focuses on building credibility through exclusive partnerships with luxury spas and boutique beauty retailers, establishing the SAMANSIC SUMO system as a premium beauty solution. Key influencer seeding targets beauty editors, wellness bloggers, and dermatologists who can validate the system's value to early adopters. The direct-to-consumer channel features a personalized onboarding experience that educates customers about cellular beauty and demonstrates the system's value proposition.

• Phase two is medical channel expansion, targeting months seven through twelve. This phase establishes the SAMANSIC SUMO system in dermatology and aesthetic medicine practices, where it can be used for treatment optimization and patient monitoring. Integrative health clinics and wellness centers provide additional professional channels. Professional association partnerships build credibility and provide access to key opinion leaders who can validate the system's clinical value.

• Phase three is mass market expansion, beginning in year two. Premium beauty retailer partnerships with Sephora and Ulta provide access to the mass premium beauty consumer market. Health and wellness e-commerce platforms expand the digital distribution reach. International expansion targets key markets with high beauty spending and receptivity to technology-enabled solutions.

• The marketing messaging focuses on the core value proposition: beauty, measured at the cellular level. The emphasis is on data-driven personalization rather than vague promises, with clinical validation and professional endorsements providing credibility. The marketing strategy builds demand through education and thought leadership, while the sales strategy converts demand through compelling demonstration and clear value articulation.

​

SLIDE 9: FINANCIAL PROJECTIONS

• The financial projections for the SAMANSIC SUMO system demonstrate strong growth and attractive margins across the first three years of operations.

• Year one projections assume 5,000 device sales at an average price of $399, generating $1.99 million in device revenue. The supplement subscription base reaches 5,000 monthly subscribers at $84 per year, generating $0.42 million in recurring subscription revenue. Premium report sales add $0.15 million, bringing total year one revenue to $2.56 million.

• Year two projections show significant growth with 10,000 device sales generating $3.99 million, 10,000 supplement subscribers generating $0.84 million, and premium report revenue reaching $0.35 million, for total revenue of $5.18 million.

• Year three projections show accelerated growth with 24,000 device sales generating $9.57 million, 24,000 supplement subscribers generating $2.01 million, and premium report revenue reaching $0.85 million, for total revenue of $12.43 million.

• Gross margins are projected at 65 percent for device sales and 75 percent for supplement subscriptions, creating a highly profitable recurring revenue stream. The supplement subscription model generates customer lifetime value that far exceeds the initial device sale, creating a compelling unit economics picture.

• These projections are based on realistic assumptions about market adoption, customer acquisition costs, and retention rates. The projections align with industry benchmarks for premium beauty devices and subscription-based wellness products.

​

SLIDE 10: INVESTMENT REQUIREMENTS

• The seed round of $2 million will fund the critical development and launch activities necessary to bring the SAMANSIC SUMO system to market.

• Research and development receives 30 percent of the funding, covering finalization of the SCB-VAD hardware design, completion of the EGB-AI Omega platform development, and ongoing clinical validation studies. This investment ensures that the system delivers on its promise of accurate cellular beauty assessment and evidence-based recommendations.

• Manufacturing setup receives 25 percent of the funding, establishing the supply chain, manufacturing partnerships, and quality control systems necessary for reliable device production. This investment ensures that the devices can be produced at scale with consistent quality.

• Marketing and sales receives 20 percent of the funding, covering the premium launch activities, influencer seeding program, direct-to-consumer marketing, and sales team development. This investment drives initial customer acquisition and establishes market position.

• Regulatory approvals receive 15 percent of the funding, covering the FDA 510(k) submission and clearance process, CE mark compliance, and other international regulatory requirements. This investment is essential for market access and clinical credibility.

• Operations and staff receive 10 percent of the funding, covering initial team hiring, facility costs, and operational expenses during the pre-revenue period.

• The key milestones to be achieved with the seed funding include prototype completion and initial clinical validation in Q1 2026, FDA submission and manufacturing partner selection in Q2 2026, regulatory clearance and pilot launch in Q3 2026, and full market launch and Series A preparation in Q4 2026.

​

SLIDE 11: THE TEAM

• The SAMANSIC SUMO system requires a diverse team with expertise spanning biomedical engineering, artificial intelligence, regulatory affairs, beauty industry marketing, and supply chain management.

• The core team includes a biomedical engineering lead with expertise in photoplethysmography and medical device development, an AI and machine learning specialist with experience in biological data analysis, a regulatory affairs expert with FDA 510(k) submission experience, a beauty industry marketing professional with distribution network connections, and a supply chain and manufacturing expert with medical device production experience.

• The advisory board brings complementary expertise. SUMOylation research scientists provide scientific validation and research connections. Clinical dermatologists provide clinical validation and professional network access. AI and wearables technology experts provide technical guidance and industry connections. Beauty industry executives provide market insight and distribution relationships.

• Strategic partnerships are critical to success. Research institutions provide the clinical validation studies necessary for regulatory submission and professional credibility. Manufacturing partners provide the production capacity and quality systems necessary for reliable device production. Supplement manufacturing partners provide GMP-certified production of the SAMANSIC SUMO formula.

• The team's combined expertise ensures that the SAMANSIC SUMO system can successfully navigate the complex path from concept to market launch, delivering on its promise of cellular beauty measurement and optimization.

​

SLIDE 12: TRACTION AND NEXT STEPS

The SAMANSIC SUMO system has already achieved significant progress toward market launch.

• Completed work includes proprietary optical sensor design validation, confirming the multi-wavelength sensor's ability to capture the cellular metabolism signals necessary for beauty assessment. The EGB-AI Omega platform architecture is complete, providing the foundation for remote AI-powered analysis. SUMOylation biomarker correlation research has established the scientific basis for cellular beauty assessment. A phase one device prototype has been completed and is undergoing testing. The intellectual property strategy has been developed, with patents filed to protect the proprietary technology.

• The next milestones are critical to market launch. Regulatory submission for FDA 510(k) clearance is targeted for Q2 2027, a process that requires approximately six months for review and approval. Clinical validation studies are scheduled for Q3 2027, establishing the correlation between SCB-VAD metrics and SUMOylation biomarkers in the target population. Manufacturing scale-up is targeted for Q4 2027, establishing the production capacity for market launch. Market launch is scheduled for Q1 2028, with full commercialization beginning in Q2 2028.

• The $2 million seed round will fund these milestones, enabling the SAMANSIC SUMO system to reach market launch and begin generating revenue. The Series A round of $8 million is planned for expansion, supporting market scaling, product line extension, and international expansion.

​

SLIDE 13: THE VISION

• The SAMANSIC SUMO system is the beginning of a larger vision to transform beauty from guesswork into data-driven science.

• The long-term vision is to create the quantified beauty category, establishing cellular beauty measurement as a standard component of beauty and wellness. The SAMANSIC SUMO system will build the world's largest cellular beauty database, enabling predictive beauty optimization and population-level insights. The system will enable women to take proactive control of their beauty and vitality, moving beyond reactive treatment to proactive optimization.

• The vision extends beyond cosmetics to healthspan extension. By supporting SUMO pathway function, the SAMANSIC SUMO system helps maintain cellular health that supports overall wellness and vitality. The system embodies the convergence of beauty and health, recognizing that true beauty radiates from cellular health.

• The competitive advantages that will ensure success include first-mover advantage in cellular beauty measurement, proprietary technology and intellectual property protection, a recurring revenue ecosystem that creates high customer lifetime value, and a foundation in established scientific research that provides credibility and validation.

• The SAMANSIC SUMO system invites investors to join in revolutionizing beauty at the cellular level, creating a new category that will transform how women approach beauty and wellness.

​

SLIDE 14: SUMMARY AND ASK

• The SAMANSIC SUMO Cellular Beauty & Vitality Assessment System represents a paradigm shift in beauty assessment and optimization. By measuring beauty at the cellular level through the emerging science of SUMOylation, the system provides women with objective data about their cellular health and personalized recommendations for optimization.

• The key points for investors to remember are that the problem is substantial—women invest billions in beauty without objective measurement of effectiveness. The solution is comprehensive—an integrated ecosystem of device, AI analysis, and supplements. The market is massive and growing—$2.68 billion in 2026 growing at 19.9 percent CAGR. The competitive advantage is unique—no direct competitors and proprietary technology. The business model is resilient—three revenue streams with high margins and recurring revenue. The team is exceptional—combining biomedical, AI, regulatory, and beauty industry expertise. The vision is transformative—creating the quantified beauty category and extending the human healthspan.

• The ask is for $2 million in seed funding to reach market launch. The funds will be used for final research and development, manufacturing setup, marketing and sales, regulatory approvals, and initial operations. The milestones to be achieved with the funding include prototype completion, regulatory submission and clearance, clinical validation, and full market launch.

• The investment opportunity is compelling because the SAMANSIC SUMO system is positioned at the intersection of three rapidly growing markets: beauty devices, wellness technology, and personalized health. The system's unique value proposition, proprietary technology, and recurring revenue model create a path to substantial returns.

• The closing message is that SAMANSIC SUMO is not just a product—it is a movement to transform beauty from guesswork into data-driven science. It is an invitation to join in revolutionizing how women approach beauty, health, and vitality. The time is now, the market is ready, and the SAMANSIC SUMO system is poised to lead.

​​

SAMANSIC SUMO™ - Measure, Optimize, Transform.